Y-mAbs has developed a set of proprietary capabilities for the development of investigational biologics that are being studied in clinical trials. Our product development team includes some of the most talented and experienced professionals in the antibody industry.
The Y-mAbs Laboratories, located in Nutley NJ, is a state-of-the-art facility for the development of antibody-based therapeutic and diagnostic agents for cancers of high unmet medical need. Y-mAbs is currently developing investigational monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), vaccines, radioimmunotherapies, and diagnostics. Antibody discovery is accomplished through selection from fully human antibody phage display libraries or hybridoma methods, which is then followed by advanced protein engineering for optimizing affinity, function, stability, manufacturability, and reduced risk of immunogenicity.
Y-mAbs’ protein engineering approach incorporates a core strategy, relying on a rational design approach, in which scientists use their detailed knowledge of the structure and function of proteins to make desired changes. We combine this rational design strategy with advanced display and selection technologies to develop investigational therapeutic and diagnostic products. In partnership with Memorial Sloan Kettering Cancer Center (MSKCC), we have developed advanced antibody platform technologies and are investigating the clinical potential of these platforms.
The clinical and regulatory groups at Y-mAbs oversee all stages of product development, from early-stage clinical trials through license application, submission, product approval, and beyond. Y-mAbs is leading the clinical development of our investigational product candidates targeting the anti-ganglioside or disialoganglioside, GD2 antibody and the B7-H3 originating from and created by MSKCC. We are currently supporting a series of active clinical programs that include Phase I/II and Phase II trials.
